Clinical Outsourcing Strategies 2017 Participant Bio/Pharma Companies
Exhibition & Sponsorship Enquiry From
Why Exhibit or Sponsor the COS symposium:
COS has been in motion as an annual event for several years serving a platform for Service and Solution providers catering to clinical trials across all phases. However the primary purpose of the symposium is content. The conference explores End – to – End Clinical Trial Outsourcing, focusing on a balanced mixture of Clinical Outsourcing and Clinical Operations.
With pharmaceutical, Biopharmaceuticals, Biotechs and Academic Partnership representatives presenting in-depth perspectives on optimal approach to clinical trial outsourcing and operations.
The platform has proven pivotal for all exhibiting and sponsoring companies in demonstrating offerings Clinical Outsourcing and Clinical Operational decision and budget holders. While sponsoring (pharma) companies have found the in-depth meetings and personalized agenda of most interest in managing on-site daily activities. As a clinical research organization you can expect a pre-scheduled 1-2-1 meetings in your private area. And engaging with traffic to allow sampling, showcasing of your capabilities and capacities as a Clinical Trial Service provider. Tenders have been allocated subject to such meetings. The opportunity is provided to you to raise awareness of your company and your contributions to the industry with products and services you provide, surrounded by sponsors, business associates and partners.
You may wish to engage COS 2017 Symposium based on showcasing, mass education and or as branding initiative, we recommend that you make a direct enquiry.
> FREE WEBINAR REGISTRATION
available for 2018?
> PREARRANGED 1-TO-1 MEETINGS
> Free registration to a series of webinars dedicated in clinical outsourcing & operations and conducted by the industry's experts
> Learn more and benefit from 1-to-1 prearranged meetings between pharmaceuticals and CROs in a private space.
Keyrus is a full CRO with a reputation among its clients for transparency, integrity and complete openness. The company is highly focused on being able to deliver with excellence – while the key and the most important differentiation is based on ‘Human’ aspect of its service provision. That is Keyrus has learned to differentiate based on exceptionally high caliper staff, positing itself as a key player in providing ‘expertise’ based on intelligence and transparency. The full range of service offerings include Project Management, Clinical Operations, Pharmacovigilance, Quality Assurance, Regulatory Affairs Strategy and Support, Data Management, Medical review & coding, Biostatistics, Medical Writing and Medical Information.
Clinitude is a privately owned CRO with more than 10 years of experience, specialized in cross-border clinical research consultancy with in depth experience in submitting and conducting clinical trials in Europe and Asia. Handling the diversity and complexity in local laws and regulations for each country is one of our expertises. Clinitude is unique in an environment where delays and cost overruns are considered normal, while we guarantee a cost effective efficient timely approach with our new CRA liaisons. Our game changer attitude has resulted in tailored solutions centralised around our head offices in Belgium, Singapore, the Philippines and US.
Cato Research is an international, full-service CRO with offices across North America, Europe, Israel and South Africa. Our multidisciplinary approach to drug development and our highly experienced professionals have successfully contributed to numerous development programs leading to marketing approvals in Europe and the US throughout the past 30 years.
Our broad spectrum of services includes regulatory affairs, management and monitoring of clinical trials, oversight management, as well as medical and pharmacovigilance. We have a proven track record in successfully managing translational medicine, complex phase 1 and 2, as well as orphan drug indication programs.
Cato’s added-value is based on a combination of quality people, quality data and quality service guaranteeing operational and service excellence.
As the EDC specialists OmniComm understands the power that an information-driven clinical enterprise can bring to your clinical research organization.
OmniComm is the only company that provides a choice of best-of-breed EDC platforms that are purpose-built for Early Phase, Late Phase, Phase I-IV, device trials, and Investigator Initiated studies.
We provide the most advanced open and interoperable EDC platforms. Our innovative clinical cloud makes insight driven data-based critical decisions possible, bringing medical therapies to patients faster with lower risk and the reason why 4 of 5 top CROs and 7 of 10 largest Phase I Clinics run OmniComm EDC technologies. www.omnicomm.com
Specializing in the musculoskeletal field, Artialis provides a complete and customized solution of preclinical studies and clinical trials including innovative biomarkers, medical imaging, and functional tests. Artialis differentiates from other CRO by developing innovative biomarkers for evaluating the progression of musculoskeletal diseases on biological, structural, and functional levels.
The company's activities are built around three complementary areas:
- Tailor-made solutions for clinical and preclinical studies (ISO 9001 certification)
- Technical and scientific expertise in R&D dedicated to the musculoskeletal field (ISO 9001 certification)
- Design, development, and commercialization of ELISA kits (ISO 13485 certification).
Clintec International is an innovative, midsized, full-service global Contract Research Organisation and Functional Service Provider specialising in Oncology, Rare Diseases and a variety of indications. With a local presence in over 50 countries, Clintec has built a world-class team of permanent employees and country management delivering a high-quality, customer-centric service. As an entrepreneurial and award-winning business, Clintec is at the forefront of conducting clinical research programmes worldwide, including unique access to emerging markets such as Turkey, Middle East and Africa.
Clintec customises each engagement through a consultative and flexible approach, aligning every solution and service to the client’s individual requirements.
Over 10,000 qualified tissue specimens available for use by public and private research organizations. All diseases and organs - selectable based on your needs.
1st FRENCH PATHOLOGY BIOBANK
MEDIPATH collects, stores and gives access to a vast selection of biological pathology samples via its tumor bank: France Tissue Bank® Specimens & Data. MEDIPATH has been granted authorization for specimens sourcing activity by the French Ministry of Higher Education, Research and Innovation (“Authorization No. AC-2016-2707”
Over 40 pathologists from 9 different sites Over 500,000 files including 25,000 diagnosed cancer cases per year Over 50 healthcare institution partners Over 5,000 connected clinicians 1st French facility accredited NF EN ISO 15189 by Cofrac. Accreditation No. 8-3052, scope and sites available on www.cofrac.fr Participation to recognized, independent, French (AFAQAP) and international (UK-NEQAS, QCMD) quality programs/surveys Member of the panel of experts on rare diseases of the French National Cancer Institute (INCa)
With more than 200,000 tissue/ biopsy specimens and more than 300,000 liquid cytology specimens characterized each year, Medipath provides a biobank of biological tumor samples (tissue, slides, pap smears) for a wide range of organs and diseases.
France Tissue Bank® Specimens & Data A database containing more than 10,000 FFPE pathological and normal tissue specimens (primary tumors and metastases, inflammatory diseases) from all organs and diseases A wide range of liquid-based cytology specimens Two data types: raw biological pathology material or characterized by our pathologists Data stored and provided according to applicable regulations
WHY usinG France Tissue Bank® Specimens & Data? a Our CONFideNtiaLitY regardiNg • Personal information (data privacy agreement, anonymized specimens, secured data system) • Your research activities (non-disclosure agreement, contracts between interested parties: material transfer agreement (MTA) or collaboration agreement) a The QuaLitY of the specimens and related data (implementation of good practices, indicatorbased quality control of all processes) a aCCeSS to biological pathology resources a Our reSpONSiVeNeS
Klinar CRO was established as an Optimum CRO enterprise for the international trials conducted in Turkey. Both companies are conducting clinical trials since September 2000 in Turkey.
Our companies has a deep experience over the clinical trials of different phases and types and post marketing surveillance studies.
With our extensive background in this field, our specialized team and with the philosophy of continous improvement, we are ensuring to provide the services you need with the excellent process.
Klinar CRO has become one of the first certified CRO to be approved by the Ministry of Health in Turkey, working in compliance with the principles of “Guideline For Good Clinical Practices”.
For more information: www.klinar-cro.com
MEDIPATH, larger French networks of Pathology Laboratories offers you its tissues sourcing services through its tumors bank: France Tissue Bank® - FTB Specimens & Data.
MEDIPATH has been granted ministerial authorizations for specimens sourcing / transfer / exportation activity.
With over 500,000 files processed each year (250,000 solid tissues, 250,000 liquid pap smears) including 25,000 diagnosed cancer cases per year, Medipath - FTB gives you access to very large inventory of highly characterized tissues (IHC + Molecular Biology data associated to each block / liquid pap smear).
MEDIPATH offers you as well all Pathology technical services you may subcontract.
One contact address: FranceTissueBank@Medipath.fr
- Premier Research Group Ltd , provides clinical development services to biotech and specialty pharma companies worldwide. Its services include clinical monitoring, project management, clinical research, late phase (phase IV) research, data management, biostatistics, regulatory affairs, medical affairs, pharmacovigilance, technology, strategic sourcing, interactive voice/Web response system, medical writing, and quality assurance. The company offers clinical development programs with a focus on addressing unmet needs in areas, such as analgesia, hematology/oncology, neuroscience, pediatrics, cardiovascular, medical device and diagnostics, and rare diseases.
Premier Research is not about being everything to everyone. Instead, our deep, focused expertise targets the therapeutic areas and indications where today’s biotech and specialty pharma pioneers are doing the most amazing work. We’re 1,000 employees strong and operate in more than 20 countries, delivering unmatched expertise, operational skills, and dedication to meeting customers’ most challenging needs.
Premier Research Group Ltd. was founded in 2002 and has locations in United Kingdom, Australia, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Romania, the Russian Federation, Slovak Republic, Spain, Ukraine, and the United States.
“As a global CRO I can inform you that we have sponsored for several years, and the 1-2-1 meetings are the only reason we are returning annually. It simply works for us and as stated previously we will support the 2017 symposium.”
MetaCell s.r.o. is developing and commercializing a device and methodology to isolate and grow in culture rare circulating cells including circulating tumor cells (CTCs) and rare circulating endometrial cells. The device consists of a tube and membrane to isolate cells from blood or other fluids, a platform to grow the cells. The method is gentle leading to 99% recovery of viable cells which are cultured in traditional medium. Cellular biomarkers can be identified and the cells tested for sensitivity to therapeutics and other anti-cancer agents.
The device has potential as a research and detection tool to assess tumor metastasis and aid in selection of targeted therapeutics. MetaCell s.r.o. is currently commercializing the device through:
1) a contract drug research and evaluation service to pharmaceutical and biotechnology companies.
2) direct sales to the diagnostic and research community worldwide.